Expression of lysyl oxidase in human osteosarcoma and its clinical significance: A tumor suppressive role of LOX in human osteosarcoma cells

Xu,Xin; Wang,Bin; Xu,Yanling

doi:10.3892/ijo.2013.2067

Expression of lysyl oxidase in human osteosarcoma and its clinical significance: A tumor suppressive role of LOX in human osteosarcoma cells

Authors:
- Xin Xu
- Bin Wang
- Yanling Xu
View Affiliations

Affiliations: Department of Orthopedic Surgery, Shanghai No. 6 People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200233, P.R. China
Published online on: August 21, 2013 https://doi.org/10.3892/ijo.2013.2067
Pages: 1578-1586

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysyl oxidase (LOX) is an extracellular matrix (ECM) remodeling enzyme, which is involved in the development and progression of many types of tumors. LOX dysfunction is observed in colorectal, breast and ovarian cancer. However, the precise effects and molecular mechanisms of LOX action in osteosarcoma progression are still unknown. We evaluated the role of LOX in human osteosarcoma cell lines and clinical tumor samples in order to determine the function of this molecule. In our study, we showed that the expression level of LOX mRNA and protein were decreased in human osteosarcoma tissues as compared with normal tissue samples. In addition, we employed adenovirus-mediated overexpression of LOX in U-2OS and HOS cells to investigate the role of LOX in osteosarcoma cell lines. Adenovirus-mediated overexpression of LOX could efficiently increase the expression levels of LOX in osteosarcoma cell lines at both mRNA and protein levels. Increased expression of LOX inhibited the proliferation and migration of human osteosarcoma cells and promoted its apoptosis. Moreover, the Ki-67 and PCNA expression was decreased and MMP-2 and MMP-9 expression was inhibited. These findings also indicated that the effects of LOX may be mediated via the PI3K/AKT signaling pathway since LOX-mediated functions could be blocked by β-aminopropionitrile (β-APN), a LOX inhibitor. Taken together, our data indicated that LOX may be a tumor suppressor and could be regarded as a therapeutic target in human osteosarcoma.

View Figures

View References

1.	Thompson L, Wang S, Tawfik O, et al: Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. J Orthop Res. 30:831–844. 2012.
2.	Chugh R: Experimental therapies and clinical trials in bone sarcoma. J Natl Compr Canc Netw. 8:715–725. 2010.PubMed/NCBI
3.	Dai X, Ma W, He X, et al: Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit. 17:RA177–190. 2011.
4.	Kagan HM and Trackman PC: Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol. 5:206–210. 1991. View Article : Google Scholar : PubMed/NCBI
5.	Kim YM, Kim EC and Kim Y: The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Bais MV, Nugent MA, Stephens DN, et al: Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One. 7:e311882012. View Article : Google Scholar
7.	Palamakumbura AH, Vora SR, Nugent MA, et al: Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene. 28:3390–3400. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Hurtado PA, Vora S, Sume SS, et al: Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun. 366:156–161. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 440:1222–1226. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Kirschmann DA, Seftor EA, Fong SF, et al: A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 62:4478–4483. 2002.PubMed/NCBI
11.	Baker AM, Bird D, Lang G, et al: Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene. 73:583–594. 2013.PubMed/NCBI
12.	Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 101:811–816. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Wu J, Cai C, Tong D, et al: Lysyl oxidase G473A polymorphism is associated with increased risk of ovarian cancer. Genet Test Mol Biomarkers. 16:915–919. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Stassar MJ, Devitt G, Brosius M, et al: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer. 85:1372–1382. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Giampuzzi M, Botti G, Cilli M, et al: Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem. 276:29226–29232. 2001. View Article : Google Scholar
16.	Bouez C, Reynaud C, Noblesse E, et al: The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res. 12:1463–1469. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Barker HE, Cox TR and Erler JT: The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 12:540–552. 2012. View Article : Google Scholar : PubMed/NCBI
18.	Novello C, Pazzaglia L, Cingolani C, et al: miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 42:667–675. 2013.PubMed/NCBI
19.	Sollazzo MR, Benassi MS, Magagnoli G, et al: Increased c-myc oncogene expression in Ewing’s sarcoma: correlation with Ki67 proliferation index. Tumori. 85:167–173. 1999.
20.	Li B, Yang Y, Jiang S, et al: Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012.PubMed/NCBI
21.	Liu ZL, Wang G, Peng AF, et al: Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 4:878–882. 2012.PubMed/NCBI
22.	Kamei S, Sakayama K, Tamashiro S, et al: Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. J Orthop Res. 27:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Duan DP, Dang XQ, Wang KZ, et al: The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep. 28:1693–1700. 2012.PubMed/NCBI
24.	Korpi JT, Hagstrom J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol. 20:e18–e22. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Zhang Y, Song L, Cai L, et al: Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food Chem Toxicol. 53C:325–333. 2012.PubMed/NCBI
26.	Rasmussen N and Rathmell WK: Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol. 6:199–206. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Kubista B, Klinglmueller F, Bilban M, et al: Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma. Int Orthop. 35:401–411. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Buchinger B, Spitzer S, Karlic H, et al: Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin. Cancer Lett. 265:45–54. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Payne SL, Fogelgren B, Hess AR, et al: Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 65:11429–11436. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Gacheru SN, Thomas KM, Murray SA, et al: Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: effects of TGF-beta 1 and serum deprivation. J Cell Biochem. 65:395–407. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Peinado H, Moreno-Bueno G, Hardisson D, et al: Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res. 68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Yu Z, Sato S, Trackman PC, et al: Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS One. 7:e332872012. View Article : Google Scholar : PubMed/NCBI
33.	Palamakumbura AH, Jeay S, Guo Y, et al: The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 279:40593–40600. 2004. View Article : Google Scholar : PubMed/NCBI
34.	Hotfilder M, Sondermann P, Senss A, et al: PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer. 92:705–710. 2005. View Article : Google Scholar : PubMed/NCBI
35.	Liu B, Shi ZL, Feng J, et al: Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int. 32:494–501. 2008. View Article : Google Scholar
36.	Jin S, Pang RP, Shen JN, et al: Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis. 12:1317–1326. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Jeay S, Pianetti S, Kagan HM, et al: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol. 23:2251–2263. 2003. View Article : Google Scholar : PubMed/NCBI
38.	Pez F, Dayan F, Durivault J, et al: The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 71:1647–1657. 2011. View Article : Google Scholar : PubMed/NCBI
39.	Voloshenyuk TG, Landesman ES, Khoutorova E, et al: Induction of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine. 55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI